Skip to content

Efficacy Study of a Device Allowing Broadcasting Maternal Voice and Heartbeat in Preterm Newborn (CALIPREM)

Pilot Study to Evaluate the Benefits of Preterm Newborn Exposition to a Maternal Voice and Heardbeat Recording During Hospital Stay

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04757012
Acronym
CALIPREM
Enrollment
30
Registered
2021-02-16
Start date
2022-04-19
Completion date
2023-06-18
Last updated
2026-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Newborn

Keywords

Preterm newborn, Maternal voice reccording, NIPE

Brief summary

The purpose of this study is to evaluate the benefits of an exposition to a maternal voice and heartbeat recording during hospital stay for preterm newborns. For that, we use of a specific neonatal device "Calinange" able to record maternal voice and heartbeats and to restore it with a sound level control. We hypothesize an improvement of the well being of the newborn under Calinange exposition.

Detailed description

Immediately after birth, preterm newborns are immersed in a hostile environment of intensive care unit with light, sound and painful stimulations. Previously, exposure to maternal voice has demonstrated improvement on infants' statements: reduction of bradycardia, desaturation events, improvement of tolerance feeding and sleep. Unfortunatly in most of the N ICU in France, the mothers' presence attendance time is reduced because of the absence of accommodation structure. The use of a specific neonatal device able to daily record maternal voice and hearbeats and to restore it when mother is gone could improve the environment and promote the well-being of the newborn.

Interventions

DEVICEcalinange

calinange

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER
URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
No minimum to 7 Days
Healthy volunteers
No

Inclusion criteria

* hospitalised premature newborn in Port-Royal NICU * age between 3 and 6 daysof life * gestational age between 27+0 and 31+6 weeks * hospitalisation in one bed room * parental consents * beneficiaries social security scheme

Exclusion criteria

* occurrence of one or more non-inclusion criteria * Non-inclusion Criteria: * Chromosomal abnormality, severe congenital malformation * Toxic substance consumption during pregnancy * Sedative medication in progress, High frequencies ventilation in progress * Neurological damage: intraventricular haemorrhage stage 3 and 4, bilateral and expanse periventricular leukomalacia lesions * Severe infectious state requiring haemodynamic support (inotropic drugs or hemissucinate) * Participation to a other intervention research

Design outcomes

Primary

MeasureTime frameDescription
Heart rate variability / NIPE IndexChange of the NIPE index before and after intervention. Each baby is his own control. Nipe index is recorded 10 minutes before and 10 minutes after the intervention (Calinange (day 2/4/6) or nothing (day 1/3/5))Recorded heart rate

Secondary

MeasureTime frameDescription
Number of desaturation eventsChange of the NIPE index before and after intervention. Each baby is his own control. Nipe index is recorded 10 minutes before and 10 minutes after the intervention (Calinange (day 2/4/6) or nothing (day 1/3/5))Change in desaturation events before and after intervention
Number of apnoeic eventsChange of the NIPE index before and after intervention. Each baby is his own control. Nipe index is recorded 10 minutes before and 10 minutes after the intervention (Calinange (day 2/4/6) or nothing (day 1/3/5))Change in apneic events before and after intervention
Number of bradycardia eventsChange of the NIPE index before and after intervention. Each baby is his own control. Nipe index is recorded 10 minutes before and 10 minutes after the intervention (Calinange (day 2/4/6) or nothing (day 1/3/5))Change in bradycardia events before and after intervention
Evaluate the benefits for the nursesTo be completed after each use of calinange ether on day 2, 4 and 6Evaluation questionnaire
Evaluate the benefits for the motherAt day 7, after the end of interventionSatisfaction questionnaire

Countries

France

Contacts

PRINCIPAL_INVESTIGATORJuliana PATKAI, MD

Service de Médecine et Réanimation néonatales de Port-Royal APHP.Centre - Université de Paris. Site Cochin.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 2, 2026